A5013787519- Cystic Fibrosis Research Advances
- Advanced biosensing and bioanalysis techniques
- Inhalation and Respiratory Drug Delivery
- Innovative Microfluidic and Catalytic Techniques Innovation
- Phenothiazines and Benzothiazines Synthesis and Activities
- Neonatal Respiratory Health Research
- Computational Drug Discovery Methods
- Respiratory viral infections research
- Chemistry and Chemical Engineering
- Pharmacological Receptor Mechanisms and Effects
Ospedale Policlinico San Martino
2025
University of Genoa
2020-2022
Cystic fibrosis (CF) is the autosomal recessive disorder most recurrent in Caucasian populations. Different mutations involving cystic transmembrane regulator protein (CFTR) gene, which encodes CFTR channel, are involved CF. A number of life-prolonging therapies have been conceived and deeply investigated to combat this disease. Among them, administration so-called modulators, such as correctors potentiators, led quite beneficial effects. Recently, based on QSAR (quantitative structure...
Cystic fibrosis (CF) is the autosomal recessive disorder most recurrent in Caucasian populations. To combat this disease, many life-prolonging therapies are required and deeply investigated, including development of so-called cystic transmembrane conductance regulator (CFTR) modulators, such as correctors potentiators. Combination therapy with two series drugs led to approval several multi-drug effective treatments, Orkambi, recent promising evaluation triple-combination...
Cystic fibrosis (CF) is a genetic disease affecting the lungs and pancreas causing progressive damage. CF caused by mutations abolishing function of CFTR, protein whose role chloride's mobilization in epithelial cells various organs. Recently therapy focused on small molecules has been chosen as main approach to contrast CF, designing synthesizing compounds acting misfolding (correctors) or defective channel gating (potentiators). Multi-drug therapies have tested with different combinations...
Sigma receptors (σRs), initially classified as an additional class of opioid receptors, are now recognized a unique entity with no homology to divided into two distinct subtypes, namely σ1R and σ2R. σ1R-targeting ligands have been conceived explored for the treatment various neurodegenerative disorders neuropathic pain. Activation σ2R appears be involved in regulation cellular proliferation cell death.Up now, rational design novel was efficiently guided by computational methods, especially...